Keratoacanthoma
☆ Natiijooyinka Stiftung Warentest ee 2022 ee ka yimid Jarmalka, ku qanacsanaanta macaamilka ee ModelDerm ayaa waxyar uun ka hooseysay la-talinta telemedicine-ka ee lacagta lagu bixiyo.
Caadiga ah Keratoacanthoma
References
Keratoacanthoma (KA) waa buro maqaarka ah oo soo noqnoqota oo caan ku ah koritaanka degdega ah iyo kartida ay dib ugu noqon karto iskeed. Waxay caadi ahaan ku dhacdaa ragga da'da weyn, ee maqaarka cad oo leh taariikh waxyeello qorraxda. Halka ka saarista qaliinka ee la isticmaalayo goynta ama qaliinka micrographic Mohs uu yahay daawaynta caadiga ah, waxaa jira doorashooyin kale oo daawaynta ah oo la heli karo.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) waa buro heer hoose ah oo ka soo bilaabata qanjidhada maqaarka qaarkood waxayna u eegtahay squamous cell carcinoma (SCC) marka la eego mikroskoob. Waxaa jirta dood socota oo ku saabsan in KA loo kala saari doono nooc ka mid ah SCC-da duulaanka ah.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) waa nooca labaad ee ugu badan ee kansarka dadka, gaar ahaan kuwa da'da ah. Qalliinka waxaa sida caadiga ah loo isticmaalaa in lagu daweeyo cSCC, laakiin bukaannada qaarkood ee aan la qali karin ama dooran karin, doorashooyin kale sida daawaynta intralesional waa la tixgelin karaa. Daawaynta dhaqameed ee intralesional (methotrexate or 5-fluorouracil) ayaa la isticmaalay, laakiin waxaa jira cilmi baaris socda oo ku saabsan habab cusub sida immunotherapy intralesional iyo virotherapy oncolytic. Halkan, waxaan ku eegi doonaa daawaynta intralesional kala duwan ee cSCC, oo u dhaxaysa hababka caadiga ah ilaa xeeladaha goynta.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Marka la eego mikroskoob, keratoacanthoma si aad ah ugu shabbahay kansarka unugyada squamous Inkasta oo qaar ka mid ah dhakhaatiirta cilmi-nafsiga ay u kala saaraan keratoacanthoma inay tahay wax kala duwan oo aan ahayn xumaan, qiyaastii 6% kiliinikada iyo taariikhda keratoacanthoma waxay horumar u sameeyaan kansarka unugga squamous-ka ee qallafsan iyo gardarrada.
○ ogaanshaha iyo daawaynta
#Dermoscopy
#Skin biopsy